Login to Your Account

Galapagos sees GLPG-1690 bloom in Flora IPF trial

By Michael Fitzhugh
Staff Writer

Friday, August 11, 2017

Galapagos NV's autotaxin inhibitor, GLPG-1690, halted worsening lung function in adults with idiopathic pulmonary fibrosis (IPF) during the 12 weeks of a small phase IIa trial, setting the stage for it to quickly move on to late-stage testing. Top-line results of the trial, called Flora, suggest '1690 might eventually challenge Roche Holding AG's Esbriet (pirfenidone) and Boehringer Ingelheim GmbH's Ofev (nintedanib).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription